Bioavailability study of two carbamazepine containing sustained release formulations after multiple oral dose administration

Arzneimittel-Forschung/Drug Research

Volumn 48, Issue 12, 1998, Pages 1131-1137

  Wangemann, Martina ^a   Retzow, Angelika ^a   Evers, Gabriele ^b   Mazur, Dago ^b   Schug, Barbara ^b   Blume, Henning ^b  

^a ALK SCHERAX Arzneimittel GmbH   (Germany)

^b ABDA Bundesvereinigung Deutscher Apothekerverbande   (Germany)

Author keywords

Carbamazepine, bioequivalence studies, sustained release formulation; Carbamazepine 10,11 epoxide; CAS 298 46 4; Timonil retard, healthy volunteers, multiple dose

Indexed keywords

CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SUSTAINED RELEASE FORMULATION;

ADULT; ANTICONVULSANTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CARBAMAZEPINE; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DIET; HUMANS; INTESTINAL ABSORPTION; MALE;

EID: 0032443698     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Loiseau, P., Duché, B., in: R. H. Levy, R. H. Mattson, B. S. Meldrum (eds.), Antiepileptic drugs, pp. 555-566. Raven Press, New York (1995)
2. Brodie, M. J., Johnson, F. N., Rev. Contemp. Pharmacother. 8, 87 (1997)
3. Morselli, P. L., in: R. H. Levy, R. H. Mattson, B. S. Meldrum (eds.), Antiepileptic drugs, pp. 515-528. Raven Press, New York (1995)
4. Spina, E., Pisani, F., Perucca, E., Clin. Pharmacokinet. 31, 198 (1996)
5. Garnett, W. R., Levy, B., Mc Lean, A. M. et al., Epilepsia 39, 274 (1998)
6. Blume, H., Mutschler, E., Bioäquivalenz - Qualitätsbewertung wirkstoffgleicher Fertigarzneimittel. Anleitung - Methoden - Materialien (Part 3/1 Retard-Arzneimittel). Govi-Verlag, Eschborn (1993)
7. CPMP - NOTE FOR GUIDANCE, Clinical testing of prolonged-action forms with special reference to extended release forms (1987)
8. Steinijans, V. W., Hauschke, D., Clin. Res. Reg. Affairs 10, 203 (1993)
9. Midha, K. K., Ormsby, E. D., Hubbard, J. W. et al., J. Pharm. Sci. 82, 138 (1993)
10. Schuirmann, D. J., J. Pharmacokinet. Biopharm. 15, 657 (1987)
11. Hauschke, D., Steinijans, V. W., Diletti, E., Int. J. Clin. Pharmacol. Ther. Toxicol. 28, 72 (1990)
12. Glue, P., Banfield, C., Human. Psychopharmacol. 11, 97 (1996)
13. Retzow, A., Schürer, M., Schulz, H. U., Int. J. Clin. Pharmacol. Ther. 35, 557 (1997)
14. Holmes, G. L., in: R. H. Levy, R. H. Mattson, B. S. Meldrum (eds.). Antiepileptic drugs, pp. 567-579. Raven Press, New York (1995)